logo-loader

Tiziana Life Sciences files patent application for its novel coronavirus treatment technology

Published: 07:56 09 Apr 2020 BST

Tiziana Life Sciences (LON:TILS) chairman and founder Gabriele Cerrone talks Proactive London's Andrew Scott through the company's update this morning which he describes as an important step in finding a solution to the current pandemic. It's filed a patent around the direct delivery method of Anti-Interlukin-6-Receptor Monoclonal Antibodies into the lungs using a handheld inhaler or nebuliser. Cerrone adds that the technology could also be applicable for use with other FDA approved mAbs and drugs.

Proactive Analyst expects "some good news over the next 1-2 months" from...

Proactive Research Analyst Robin Davison talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd (NASDAQ:TLSA), which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months. He says Tiziana is approaching a significant...

on 28/7/23